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Quality control assessment of human immunodeficiency virus
type 2 (HIV-2) viral load quantification assays: results from an
international collaboration on HIV-2 infection in 2006
Abstract
Human immunodeficiency virus type 2 (HIV-2) RNA quantification assays used in nine laboratories of
the ACHI(E)V(2E) (A Collaboration on HIV-2 Infection) study group were evaluated. In a blinded
experimental design, laboratories quantified three series of aliquots of an HIV-2 subtype A strain, each
at a different theoretical viral load. Quantification varied between laboratories, and international
standardization of quantification assays is strongly needed.
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Human immunodeficiency virus type 2 (HIV-2) RNA quantification assays used in nine laboratories of the
ACHIEV2E (A Collaboration on HIV-2 Infection) study group were evaluated. In a blinded experimental design,
laboratories quantified three series of aliquots of an HIV-2 subtype A strain, each at a different theoretical viral
load. Quantification varied between laboratories, and international standardization of quantification assays is
strongly needed.
The human immunodeficiency virus type 2 (HIV-2) epi-
demic remains essentially confined to West Africa (4). In Eu-
rope, most of the patients live in France, Portugal, and Spain,
although patients are also found in The Netherlands, Belgium,
Luxemburg, Germany, Switzerland, Italy, the United King-
dom, and Sweden (5, 10–13). Many questions remain unan-
swered concerning the evolution of virological, immunological,
and clinical parameters under treatment. Answering these
questions requires the largest possible number of observations
and standardization of outcome measurements such as that of
the HIV-2 load in plasma. There is currently no available
commercial assay for the quantification of plasma HIV-2
RNA. In this study, we evaluated the validity of assays used for
the quantification of HIV-2 RNA among nine centers in the
ACHIEV2E (A Collaboration on HIV-2 Infection) study
group, in Belgium, France, Gambia, Germany, Portugal, Spain,
Sweden, Switzerland, and the United Kingdom, in order to
identify appropriate actions to improve the quality of these
assays. Each of the nine participating laboratories performed a
different HIV-2 RNA quantification assay (2, 3, 7–9). Labora-
tories used mainly different “in-house” real-time PCR assays
with primers and probes located in various regions of the
HIV-2 genome, and they employed different HIV-2 standards
(Table 1).
The sample panel was prepared in a single virology labora-
tory (Bichat-Claude Bernard Hospital, Paris, France) by per-
forming serial dilution of the NIHz HIV-2 subtype A super-
natant, quantified by electron microscopy (ABI Technologies),
in HIV-negative human plasma to obtain 10 1-ml aliquots each
with final HIV-2 RNA concentrations of 1.7, 2.3, and 3.0 log10
copies/ml.
The accuracy and reproducibility of assays were estimated
for the three theoretical concentrations. A quantification assay
was defined as accurate if at least 9 of the 10 measurements fell
within a clinically acceptable interval based on the NIHz the-
oretical concentrations. The interval was defined as one-third
of the theoretical viral load to three times the theoretical viral
load for theoretical viral loads of 3.0 and 2.3 log10 copies/ml
and as 0 to three times the theoretical viral load for a theoret-
ical viral load of 1.7 log10 copies/ml.
Reproducibility of assays was evaluated by using the intra-
laboratory coherence coefficient (ILCC) and the coefficient of
variation (CV) at each of the three theoretical concentrations
(1). A quantification heterogeneity was defined as an ILCC
greater than the theoretical value L, extracted from a reference
table for p laboratories and n repetitions (1).
Each of the participating laboratories quantified 35 coded
and randomized aliquots. All laboratories reported an unde-
tectable viral load for the five HIV-negative aliquots.
At a theoretical level of 3.0 log10 copies/ml, median quanti-
fications varied from 2.9 log10 copies/ml in laboratory 6 to 4.2
log10 copies/ml in laboratory 8 (Fig. 1A). Five laboratories
reported accurate measurements (i.e., 9 of the 10 quantifica-
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tions fell in the interval from 2.52 to 3.48 log10 copies/ml). The
four other assays overquantified viral loads (laboratories 1, 3,
7, and 8) (Fig. 1A). Seven laboratories reported reproducible
measurements (CV  3 to 6%; ILCC  0.5 to 0.9; L  1.35)
(laboratories 1, 2, 3, 6, 7, 8, and 9). Laboratories 2, 6, and 9
reported both accurate and reproducible measurements. At a
theoretical level of 2.3 log10 copies/ml, the accuracy and repro-
ducibility of the tests at laboratories 4 and 5 could not be
evaluated since 10 and 9 negative results were reported, re-
spectively. Median quantifications varied from 2.4 log10 cop-
ies/ml in laboratory 9 to 3.4 log10 copies/ml in laboratory 8 (Fig.
1B). Three laboratories reported accurate measurements (i.e.,
9 of the 10 quantifications fell in the interval from 1.82 to 2.78
FIG. 1. Accuracy of quantification assays evaluated by the
ACHIEV2E Collaboration in 2006. Quantification results are reported
for each participating laboratory. The accuracy interval is represented
by the white area for each of the three theoretical viral loads used.
Panels: A, theoretical viral load  3.0 log10 copies/ml; B, theoretical
viral load  2.3 log10 copies/ml; C, theoretical viral load  1.7 log10
copies/ml.
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log10 copies/ml), and four laboratories overquantified viral
loads (laboratories 1, 3, 7, and 8) (Fig. 1B). Six laboratories
reported reproducible measurements (CV  5 to 8%; ILCC 
0.5 to 1.1; L  1.35). Only two laboratories, 2 and 9, reported
both accurate and reproducible measurements.
At a theoretical level of 1.7 log10 copies/ml, the accuracy and
reproducibility of the assays used by laboratories 4, 5, 6, and 7
could not be evaluated since 9, 10, 7, and 9 negative results were
reported, respectively. The median quantifications varied from
1.4 log10 copies/ml in laboratory 2 to 2.9 log10 copies/ml in labo-
ratory 8 (Fig. 1C). Two laboratories, 2 and 9, reported accurate
measurements (i.e., 9 of the 10 quantifications were below 2.18
log10 copies/ml), and three laboratories overquantified viral loads
(laboratories 1, 3, and 8) (Fig. 1C). These three laboratories
reported reproducible measurements (CV  5 to 11%; ILCC 
0.4 to 0.8; L  1.35). At this level, no laboratories reported both
accurate and reproducible measurements.
Our study is the first international evaluation of the validity
of HIV-2 RNA quantification assays. We found a fair homo-
geneity of results of assays evaluated at a theoretical level of
3.0 log10 copies/ml and a decreasing accuracy and reproduc-
ibility of assays with decreasing viral loads, as previously shown
in a quality control study of HIV-1 RNA quantification assays
(6). Overall, four laboratories systematically overquantified vi-
ral loads, no. 1, 3, 7, and 8. Two laboratories, 4 and 5, reported
18 negative results out of 20 quantifications at theoretical viral
loads of both 2.3 and 1.7 log10 copies/ml. The thresholds of
these two assays had been evaluated at 2.7 and 2.3 log10 copies/
ml, respectively. The cutoff values of the methods used by
laboratories 5 and 7 may also explain their results for the
1.7-log10-copy/ml aliquots. One laboratory (no. 6) reported
both accurate and reproducible results at a theoretical viral
load of 3.0 log10 copies/ml but heterogeneous quantifications
at 2.3 log10 copies/ml and negative results at 1.7 log10 copies/
ml. Two laboratories, 2 and 9, reported both accurate and
reproducible results at theoretical viral loads of 3.0 and 2.3
log10 copies/ml and accurate but relatively poorly reproducible
quantifications at 1.7 log10 copies/ml. The aliquot were made
from the NIHz HIV-2 supernatant, which is the standard used
for the calibration of the laboratory 2 assay. That may have
improved the results reported by this laboratory and decreased
those observed in other laboratories such as no. 8, which has
not yet been evaluated with calibrated specimens. However,
laboratory 9, which did not use NIHz as a standard, reported
results very similar to those obtained by laboratory 2.
This study provides an overview of the performance of dif-
ferent HIV-2 RNA quantification assays. If the HIV-2 super-
natant counted by electron microscopy is accepted as a stan-
dard, only two laboratories reported accurate and reproducible
measurements at both 3 and 2.3 log10 copies/ml. This hetero-
geneity may yield difficulties in the comparison of results be-
tween the different cohorts of the ACHIEV2E Collaboration.
The ACHIEV2E network is working toward the standardiza-
tion of quantification assays to improve the interpretation of
results for case management and collaborative clinical trials.
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